<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BCL2 is deregulated in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) by the t(14;18) translocation, gene amplification and/or nuclear factor-ÎºB signaling </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="40" ids="33697">RNA</z:chebi>-seq data have recently shown that BCL2 is the most highly mutated gene in germinal center B-cell (GCB) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We have sequenced BCL2 in 298 primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> biopsies, 131 additional non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> biopsies, 24 DLBCL cell lines and 51 germline DNAs </plain></SENT>
<SENT sid="3" pm="."><plain>We found frequent BCL2 mutations in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) and <z:e sem="disease" ids="C1333295" disease_type="Neoplastic Process" abbrv="">GCB DLBCL</z:e>, but low levels of BCL2 mutations in activated B-cell <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, small lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> and peripheral T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>We found no BCL2 mutations in GC centroblasts </plain></SENT>
<SENT sid="5" pm="."><plain>Many mutations were non-synonymous; they were preferentially located in the flexible loop domain, with few in BCL2-homology domains </plain></SENT>
<SENT sid="6" pm="."><plain>An elevated transition/transversions ratio supports that the mutations result from somatic hypermutation </plain></SENT>
<SENT sid="7" pm="."><plain>BCL2 translocations correlate with, and are likely important in acquisition of, additional BCL2 mutations in <z:e sem="disease" ids="C1333295" disease_type="Neoplastic Process" abbrv="">GCB DLBCL</z:e> and FL </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> mutations were not independently associated with survival </plain></SENT>
<SENT sid="9" pm="."><plain>Although previous studies of BCL2 mutations in FL have reported mutations to result in pseudo-negative BCL2 protein expression, we find this rare in de-novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
</text></document>